Basic fibroblast growth factor (bFGF) is known to bind to its cell-surface receptors with high aitmity and in a heparin-dependent manner. In an attempt to predict the receptor recognition site on bFGF we screened phageepitope libraries with monoclonal antibodies DG2 and DE6, which inhibit bFGF binding to its receptor. On the affinityisolated phages, we identified several peptide sequences as the putative antibody-binding epitopes on bFGF. Two monoclonal antibodies (mAbs) raised against human recombinant bFGF were found to efficiently block binding of bFGF to its cell-surface receptors (17) . These two mAbs, designated DG2 and DE6, inhibited bFGF-stimulated proliferation of cultured human glioma cells and retarded rat C6 glioma growth in nude mice (18). A recent study showed that the administration of neutralizing mAbs to bFGF caused significant alterations in tumor growth in vivo and that these changes were specific for tumor type and bFGF characteristics (8). The inhibitory effects of the antibodies on bFGF binding and biological activities suggest that the bFGF epitopes recognized by the antibodies may coincide with sequences recognized by the receptor. To identify these sequences we used these antibodies to screen a phageepitope library (19).
Basic fibroblast growth factor (bFGF) is a potent heparinbinding growth factor that stimulates proliferation, migration, and differentiation of cells of mesenchymal and neuroectodermal origin (1) (2) (3) (4) . bFGF participates as an autocrine modulator of cell growth and transformation and is abundant in malignantly transformed cells (5, 6) . Recent studies demonstrate that local in vivo expression of acidic FGF (aFGF) promotes intimal hyperplasia (7) and that exogenous administration of bFGF stimulates tumor angiogenesis and progression (8) . Accumulating evidence suggests that blocking the interactions of bFGF with its receptors leads to inhibition of cell proliferation and tumor progression in vivo. For example, inhibition of FGF receptor (FGFR) 1 gene expression in human melanocytes and malignant melanomas by antisense oligonucleotides led to the inhibition of cell proliferation and the induction of differentiation (9) . Targeting of FGFR-1 by a toxic FGF-saporin complex eliminated intimal smooth-muscle-cell proliferation in an experimental restenosis model (10) .
The biological response of cells to bFGF is mediated through specific cell-surface receptors that possess intrinsic tyrosine kinase activity and are phosphorylated upon binding ofbFGF (for reviews, see refs. 2 and 3). High-affinity binding and activation of FGFRs require cell-surface heparan sulfates, which in turn modulate FGF-receptor interactions (11, 12) . Four FGFRs (denoted FGFR-1 to -4) have recently been
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identified, and their cDNA encode a multitude of structural and functional receptor variants (for reviews, see refs. [13] [14] [15] . FGFR-1 (flg) is widely expressed in a variety of tumorderived cells and tissues and is the major FGFR of vascular endothelial cells (16) . Blocking of bFGF-FGFR-1 interactions may, therefore, have important implications for inhibition of pathological angiogenesis and attenuation of unrestrained cell proliferation and cancer.
Two monoclonal antibodies (mAbs) raised against human recombinant bFGF were found to efficiently block binding of bFGF to its cell-surface receptors (17) . These two mAbs, designated DG2 and DE6, inhibited bFGF-stimulated proliferation of cultured human glioma cells and retarded rat C6 glioma growth in nude mice (18) . A recent study showed that the administration of neutralizing mAbs to bFGF caused significant alterations in tumor growth in vivo and that these changes were specific for tumor type and bFGF characteristics (8) . The inhibitory effects of the antibodies on bFGF binding and biological activities suggest that the bFGF epitopes recognized by the antibodies may coincide with sequences recognized by the receptor. To identify these sequences we used these antibodies to screen a phageepitope library (19) .
The library consists of phages bearing random hexapeptides fused to the amino terminus of the coat protein PIII. Screening of the library is accomplished by the use of a monospecific binding protein, such as an antibody, to affinity-purified phages that display a high-avidity binding peptide. The amino acid sequences ofthe hexapeptides displayed on the phage are then determined by sequencing the corresponding coding region in the phage DNA (19) . Here we describe the characterization of a series of hexapeptides synthesized according to the epitope sequences identified in the phage-epitope library by screening with mAbs DG2 and DE6. These peptides show a significant ability to inhibit high-affinity receptor binding and biological activity of bFGF.
MATERIALS AND METHODS
Materials. Human recombinant bFGF was from Takeda (Osaka). The mAbs DG2 and DE6 have been described (17) . Rabbit antibodies against human placenta alkaline phosphatase (AP) or against phage M13 were generated by immunization using a standard procedure (20 (21) . Conditioned medium from cells secreting FGFR-1-AP fusion protein (21, 22) was incubated for 45 min at room temperature with rabbit anti-human placental AP antibodies prebound to agarose-protein A beads (Pierce). The FGFR-1-coupled beads were washed three times with 1 ml of 20 mM Hepes, pH 7.5/150 mM NaCl/1% Triton X-100/109o (vol/vol) glycerol (HNTG medium) and incubated with 125I-labeled FGF at 2 ng/ml, heparin at 1 pg/ml, and peptides at different concentrations for 1-2 hr at room temperature. High-affinity-bound 125I-labeled bFGF was determined after three cycles of washing with HNTG medium and counting the radioactivity in the tubes with a y counter.
Binding of 'mI-Labeled bFGF to mAb DG2. Maxisorb plates (Nunc) were coated with 100 ul of rabbit anti-mouse IgG (Jackson ImmunoResearch) diluted 1:500 in 0.1 M NaHCO3. After 16 hr at 4°C the plates were washed five times with phosphate-buffered saline (PBS)/0.05% Tween 20, and mAb DG2 (100 containing 20 ng) was then added to the wells and incubated for 16 hr. After being washed as described above and being blocked with 10o low-fat milk in PBS for 1 hr, the plates were washed again, and 50 /l of 125I-labeled bFGF (0.2 ng/ml) was added in the presence ofincreased concentrations of various peptides. After 2 hr of incubation the plates were washed with HNTG medium, and the bound radioactivity was dissolved in 0.1 M NaOH and counted in a 'y counter.
Binding and Cross-Linking of 12'I-Labeled bFGF to Cells.
Confluent cultures of NIH 3T3 cells in 24-well plates (Falcon) were precooled and washed twice with cold DMEM/20 mM Hepes, pH 7.5/0.1% BSA (DMEM/BSA). They were then incubated for 1.5 hr at 4°C with 125I-labeled bFGF at 2 ng/ml in DMEM/BSA and different concentrations of peptides. The binding medium was discarded, and the cells were washed once with ice-cold DMEM/BSA and twice with cold PBS, pH 7.5, containing 1.6 M NaCl. High-affinity receptorbound bFGF was determined by extraction of the cells with 20 mM NaC2H302, pH 4.0/2.0 M NaCl. Nonspecific binding was estimated as the residual counts in the presence of a 100-fold excess of unlabeled bFGF. For cross-linking the beads were resuspended in 0.4 ml of 0.15 mM disuccinylimidyl suberate (Pierce) in PBS for 30 min, washed with PBS, and boiled for 5 min in sample buffer [50 mM Tris, pH 6.8/25% (vol/vol) glycerol/6% (vol/vol) 2-mercaptoethanol/4% (wt/vol) SDS/1 mM EDTA/10% (wt/vol) bromophenol blue]. The protein complexes were run on a SDS/7.5% polyacrylamide gel. The gel was dried and exposed to x-ray film (Agfa).
Cell Proliferation Assay. Bovine aortic endothelial cells were seeded in 24-well plates (5000 cells per well) in DMEM/ 10% bovine calf serum. Peptide, dissolved in PBS and filtered, was added every day for 1-6 days, according to the experimental design. Cells were removed by trypsin, and radioactivity was counted after 6 days or every other day with a Coulter Counter.
DNA Sequencing. Phages from the supernatants of positive colonies were precipitated with polyethyleneglycol, and their DNA was prepared by phenol extraction. DNA was sequenced by the chain-termination method with the aid of a described primer (19) .
RESULTS

Isolation of Phages Displaying bFGF Epitopes from the
Hexapeptide Epitope Library. Our approach is based on the assumption that antibodies that neutralize bFGF and block receptor binding may recognize bFGF epitopes that participate in the binding of bFGF to the FGFR. To identify such epitopes on bFGF we screened the hexapeptide phageepitope library with the two mAbs DG2 and DE6, shown previously to potently inhibit bFGF binding in vitro (17) and in vivo (18) . After three cycles of panning and phage amplification, the individual phages derived from each mAb screen were grown, and their epitope-encoding regions were sequenced. The results shown in Table 1 indicate that mAbs DG2 and DE6 bind to similar epitopes, most of which share the consensus epitope sequence P(P/S)GH(Y/F)K (singleletter amino acid code). Sequence comparison with bFGF revealed two possible homologous sequences that may represent the authentic epitopes on bFGF-namely, PPGHFK and RTGQYK at aa 13-18 and 120-125, respectively. ELISA analysis of the binding of the two mAbs to their corresponding epitope-presenting phages showed that phages isolated by one antibody cross-react with the other antibody, suggesting that the two antibodies may recognize a similar epitope (data not shown, see also nant of bFGF that may be involved in both antibody and FGFR-1 binding. In this system the peptide KRTGQYKL (residues 119-126 of bFGF) is a better inhibitor than peptide PPGHFK (residues 13-18 of bFGF), in contrast to the inhibition pattern of the two peptides when tested on antibody binding to the phages (Fig. 1) .
We GQYKL, efficiently blocked cross-linking of '251-labeled bFGF to its receptor at peptide concentrations of 20 ng/ml.
Epitope-Library-Derived Peptides Inhibit Endothelial Cell Proliferation. Fibroblast growth factors stimulate endothelial cell proliferation and migration in vitro and are potent angiogenic factors in vivo (1). We therefore tested the effects of the epitope-library-derived peptides on the proliferation of bovine aortic endothelial cells. As can be seen in Fig. SA , daily additions of either APSGHYKG or KRTGQYKL at 1 .ug/ml completely inhibit the basal growth of aortic endothelial cells under conditions in which the untreated cells multiplied by >10-fold. Moreover, in the presence of either phage or bFGF-epitope-derived peptides, the number of viable endothelial cells decreased with time, suggesting that the peptides interfere with endogenous bFGF-FGFR interactions in these cells, thereby affecting their survival. To determine whether the antiproliferative effect of these peptides is, indeed, due to inhibition of bFGF activity, the cells were incubated with submaximal concentrations (0.2 ,g/ml) of the phage-derived peptide APSGHYKG with or without human recombinant bFGF at 10 ng/ml. were incubated with 125I-labeled bFGF (2 ng/ml), heparin (200 ng/ml), and the indicated peptides (10 ng/ml) or antibody (1 mg/ml) in 1 ml of DMEM/0.1% BSA/20 mM Hepes, pH 7.4. After 45 min of shaking at 22°C, the beads were washed and resuspended in 0.4 ml of PBS/0.15 mM disuccinylimidyl suberate for 30 min at 22°C. After the beads were washed, they were suspended in sample buffer and run on a SDS/7.5% polyacrylamide gel. After the run, the gel was dried and exposed to x-ray film for several days. 
DISCUSSION
High-affinity ligand-receptor interaction is fundamental for the specific and diverse biological activities ofcellular growth factors and a main target for the development of growth modulators and for therapeutic intervention. Binding of FGFs to their receptors involves a complex interaction, as multiple ligands and receptor variants exist (13) (14) (15) and several structural elements in the receptor determine ligand binding and specificity (24) (25) (26) . Moreover, high-affinity receptor binding of FGF requires heparin or cell-surface heparan sulfates (11, 12) . Several attempts have been made to identify functional domains in bFGF that participate in receptor binding and could serve as bFGF antagonists (27, 28) . In an extensive survey of overlapping synthetic peptides spanning the entire primary sequence of bFGF, Baird and colleagues (27) identified two major regions suspected of involvement in ligand-receptor interaction. Peptides derived from either aa 24-68 or 103-146 of bFGF inhibited bFGF binding to the receptor and heparin, as well as bFGF-induced DNA synthesis in 3T3 fibroblasts. The carboxyl-terminal peptide includes our identified inhibitory sequence KRT-GQYKL. The shortest peptide identified as a bFGF antagonist by this synthetic peptide approach was an 18-aa-long peptide corresponding to residues 103-120 (27) . However, in spite ofthe capacity ofthese relatively long peptides to inhibit thymidine incorporation in 3T3 fibroblasts, they had no effect on either basal or bFGF-induced proliferation of endothelial cells. In a later report, Seno and colleagues (28) constructed a series of truncated bFGF molecules that lacked an amino or a carboxyl terminus and confirmed the importance of carboxyl-terminal structures in bFGF for both receptor and heparin binding.
The phage-epitope-library technology has become a powerful tool for identifying determinants recognized by antibodies and other proteins (29) . Of interest is the identification of peptide epitopes that may inhibit the binding of nonpeptidic ligands. For example, the consensus peptide Tyr-ProTyr identified in a phage-epitope library by Con A can inhibit the binding of methyl a-D-mannopyranoside to Con A (30, 31) . These and other results suggest that if the epitope is continuous (sequential determinant), the homology between phage-epitope sequences and the ligand sequence may be high, whereas in the case of a noncontiguous sequence there may be no homology at all with the sequence of the ligand.
To gain an insight into the complex and dynamic interactions of bFGF with FGFR-1 and identify structural elements that participate in FGF-receptor interactions, we screened an epitope library of hexapeptides presented on phages (19) with neutralizing antibodies to bFGF. We found that the peptides recognized by the mAbs DG2 and DE6 represent a continuous bFGF sequence. This result is supported by the ability of the peptides derived from bFGF sequences to inhibit the binding of bFGF to its receptor and by the homology between these peptides and the phage-displayed peptide.
Although the two mAbs cross-react, their relative affinities toward the various peptides and peptide-presenting phages suggest that they are unique and are directed against two distinct, though similar, epitopes on bFGF. Indirect evidence for their distinctive nature comes from a previous study demonstrating a different pattern of binding and neutralizing activity toward bFGF (17, 18) . Nevertheless, the striking similarity of the epitopes identified by the mAbs ( Table 1 ) strongly suggests that the two mAbs react, although in a somewhat different way, with the same or almost the same determinant on bFGF.
The localization of the bFGF epitope that corresponds to the phage peptide sequence is not finally conclusive because peptides from either the amino-terminal sequence (residues 13-18) or the carboxyl-terminal sequence (residues 119-126) showed inhibition of bFGF binding. It is more likely that the actual neutralizing activity of these antibodies is through binding to the carboxyl-terminal residues, in accordance with the previous localization of bFGF receptor-binding domains to either residues 24-68 or 103-146 (27) , both of which are beyond the presently identified amino-terminal sequence. Moreover, a peptide consisting of aa 106-115 of bFGF was shown to bind heparin, interact with the bFGF receptor, and be active in mitogenic assays of bFGF (27) . Recent crystallographic studies of bFGF indicate that fragment [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] forms an open loop on the surface of the bFGF molecule (32) (33) (34) . It was suggested that this region, which also constitutes the most extended segment of structural similarity between bFGF and interleukin-1f3, may form a conserved backbone conformation common to several members of this family of growth factors, whereas the amino acid residues in this backbone determine ligand-binding specificity (32) . Chemical modification studies have shown that reductive methylation of Lys-118 in aFGF completely abolishes its mitogenic activity and substantially decreases the affinity of aFGF for heparin (35) . Similar results were obtained by replacement of this lysine with glutamate (36) . Lysine-118 in aFGF corresponds to Lys-125 in bFGF, which is penultimate to the carboxyl-terminal residue in the presently identified inhibitory peptide KRTGQYKL. This result further supports the notion that the neutralizing activity of these antibodies is through binding to the carboxyl-terminal residues of bFGF rather than to the similar amino-terminal residues, which in turn actively participate in bFGF-receptor binding. Nevertheless, as the sequences presented on the phages share higher homology with the amino-terminal domain of bFGF, one cannot exclude the possibility that the antibodies were formed against this part of bFGF.
